Remove abbvie-pays-10b-acquire-immunogen-doubling-down-red-hot-adc-cancer-field
article thumbnail

AbbVie pays $10B to acquire ImmunoGen, doubling down on red-hot ADC cancer field

Fierce Pharma

The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal. | The sizzling antibody-drug conjugate field is at the center of another major life sciences deal. Hoping to redeem itself following the epic Rova-T failure, AbbVie is shelling out $10.1

319
319